Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of intangible assets

Other operating expense (income), net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Quest Diagnostics

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Quest Diagnostics reports robust 2022 performance amidst COVID-19 testing decline

Quest Diagnostics delivered strong financial performance in 2022, with revenue growth and strategic acquisitions driving expansion.
Challenges include the anticipated decline in COVID-19 testing revenues and regional healthcare recovery disparities post-pandemic.
Opportunities lie in advanced diagnostics investments, productivity enhancements, and upcoming investor day to showcase growth strategies.
Overall, Quest Diagnostics remains focused on long-term growth, margin improvement, and shareholder value creation.

Quest Diagnostics reports strong Q1 earnings, eyes growth opportunities

Quest Diagnostics' Q1 performance reflects robust revenue growth and strategic acquisitions positioning the company for future success. Challenges in margin progression and market expectations for MRD testing require attention, while opportunities in oncology distribution and consumer testing optimization offer avenues for growth.

Quest Diagnostics reports robust Q2 earnings, raises guidance amid challenges

Quest Diagnostics demonstrated strong financial performance in Q2 2023, with revenue growth, margin improvement, and raised guidance, despite challenges like high turnover and labor costs.
The company's strategic focus on innovation, acquisitions, and pricing strategies presents opportunities for sustained growth and market expansion in clinical areas like genomics and oncology.
Navigating challenges related to employee turnover and cost pressures while leveraging opportunities in M&A, value-based care, and technological advancements will be crucial for Quest Diagnostics' future success.

Quest Diagnostics reports robust Q3 earnings amidst COVID challenges

Quest Diagnostics delivered strong financial results in Q3, showcasing growth in base business and adjusted EPS. While facing challenges from COVID-19 testing revenue decline and regulatory uncertainties, the company remains focused on leveraging opportunities in growth investments and margin improvements.

Quest Diagnostics reports robust 2023 performance and optimistic 2024 outlook

Quest Diagnostics delivered strong financial performance in 2023, with revenue growth driven by acquisitions and strategic initiatives.
The company's focus on oncology, Alzheimer's offerings, and AI tools deployment positions them for continued growth and innovation.
While facing short-term challenges like regulatory uncertainties and pricing pressures, Quest Diagnostics remains confident in their long-term outlook and growth prospects.
With a positive guidance for 2024, including revenue and EPS expectations, the company aims to navigate headwinds and capitalize on opportunities for sustainable growth.

Quest Diagnostics reports robust Q1 results and strategic growth plans

Quest Diagnostics' Q1 performance showcased strong revenue growth and strategic investments in advanced diagnostics and automation.
While facing challenges like regulatory concerns and pricing pressures, the company's focus on acquisitions and operational efficiency drives growth.
Opportunities lie in continued automation efforts, market expansion in advanced diagnostics, and the positive outlook for key acquisitions.
Overall, Quest Diagnostics' solid financial results and raised guidance reflect a resilient business poised for future growth.

Quest Diagnostics reports robust Q2 earnings amid strategic acquisitions

Quest Diagnostics' Q2 2024 performance reflects solid revenue growth, operational efficiency, and strategic acquisitions driving expansion.
Despite challenges related to acquisition impact on EPS and industry dynamics, Quest's strong balance sheet and growth strategy position it well for the future.
The company's focus on advanced diagnostics, financial stability, and market opportunities underscores its resilience and growth potential in the healthcare sector.

Quest Diagnostics reports strong Q3 growth driven by acquisitions and advanced diagnostics

Quest Diagnostics' Q3 2024 performance reflects a robust growth trajectory driven by strategic acquisitions and a focus on advanced diagnostics.
While facing integration challenges and market uncertainties, the company's strong revenue streams and operational initiatives position it well for future growth.
With a reaffirmed long-term outlook and proactive acquisition strategy, Quest Diagnostics remains poised for continued success in the healthcare diagnostics sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Quest Diagnostics has a strong Q2 with a slight beat on EPS and revenue. Quest's base business appears to be recovering from the pandemic and pulled in $2.30B in revenue. Despite fading COVID-related revenue, Quest updated their full-year 2023 revenues to $9.12B -$9.22B. The post-COVID labor market is posing challenges, including high turnover and elevated labor costs. As a result, I have downgraded my conviction level from 5/5 to 4/5.

Quest Diagnostics: Q2 Earnings Reveal Promising Growth Trends Despite Dwindling COVID Testing Revenues

Biogen and Eli Lilly both have treatments to help reduce cognitive decline in Alzheimer's patients. But the key to their effectiveness is in treating people who have the disease in its early stages.

More Alzheimer's Treatments Are Coming: This Company Can Help With Early Detection

Ten-fold increase in death risk in individuals with high levels of myeloperoxidase, or MPO, compared to those with low levels, according to analysis of 3,700 patients of MDVIP tested by Quest Diagnostics SECAUCUS, N.J., and BOCA RATON, Fla.

Inflammation Marker Signifies Increased Mortality Risk, Finds New Study in PLOS ONE

American Tower

General Dynamics

Walking into the latter half of 2023, we're looking at a very different stock market than a year ago. Despite elevated interest rates and ongoing inflation, the S&P 500 is up for the fifth consecutive month.

Looking for a Bargain? 3 Stocks to Buy That Are Down 10% in 2023

Quest Diagnostics Inc. DGX, +0.10% said Monday it has brought the first blood-based biomarker test to assess the risk of developing Alzheimer's disease to market and it's now available for consumer purchase. The test helps assess the risk of getting the disease based on the brain protein beta amyloid which contributes to it.

Quest Diagnostics launches first at-home blood test to assess risk of developing Alzheimer's disease

Quest Diagnostics on Monday launched the first direct-to-consumer blood test to detect abnormal levels of beta amyloid, a key Alzheimer's protein which can appear years before dementia symptoms arise.

Quest Diagnostics launches Alzheimer's blood test for consumers

AD-Detect™ Test for Alzheimer's Disease is the first blood-based biomarker test for assessing beta amyloid protein, a recognized marker of Alzheimer's disease, available for consumer purchase to help individuals identify their risk of developing Alzheimer's disease Physician oversight included in offering, helping individuals interpret results and determine next steps SECAUCUS, N.J. , July 31, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the leader in diagnostic information services, today announced the availability of the AD-Detect™ Test for Alzheimer's Disease on questhealth.com – the first blood test available for consumer purchase that helps assess potential risk of developing Alzheimer's disease based on a brain protein that contributes to the condition.

Quest Introduces First-To-Market Consumer-Initiated Blood Test for Alzheimer's Disease Risk Assessment on questhealth.com

Quest Diagnostics, Inc. (NYSE:DGX ) Q2 2023 Earnings Conference Call July 26, 2023 8:30 AM ET Company Participants Shawn Bevec - VP, IR James Davis - Chairman, CEO & President Sam Samad - EVP & CFO Conference Call Participants Jack Meehan - Nephron Research Elizabeth Anderson - Evercore ISI A.J. Rice - Crédit Suisse Lisa Gill - JPMorgan Chase & Co. Eric Coldwell - Robert W.

Quest Diagnostics, Inc. (DGX) Q2 2023 Earnings Call Transcript

Quest Diagnostics (DGX) delivers better-than-expected earnings and revenues in the second quarter of 2023.

Quest Diagnostics (DGX) Q2 Earnings Beat Estimates, FY View Up

Quest Diagnostics (DGX) came out with quarterly earnings of $2.30 per share, beating the Zacks Consensus Estimate of $2.23 per share. This compares to earnings of $2.36 per share a year ago.

Quest Diagnostics (DGX) Surpasses Q2 Earnings and Revenue Estimates

Laboratory operator Quest Diagnostics Inc beat estimates for quarterly profit on Wednesday, as people returned for regular checkups and tests that were delayed during a large part of the COVID-19 pandemic.

Quest Diagnostics beats profit estimates as routine testing picks up

Second quarter revenues of $2.34 billion, down 4.7% from 2022 Second quarter reported diluted earnings per share ("EPS") of $2.05, up 4.6% from 2022; and adjusted diluted EPS of $2.30, down 2.5% from 2022 Second quarter base business revenues of $2.30 billion, up 9.5% from 2022 Full year 2023 revenues now expected to be between $9.12 billion and $9.22 billion; reported diluted EPS now expected to be between $7.52 and $7.92; and adjusted diluted EPS expected to be between $8.50 and $8.90 SECAUCUS, N.J. , July 26, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the second quarter ended June 30, 2023.

Quest Diagnostics Reports Second Quarter 2023 Financial Results; Updates Guidance for Full Year 2023

Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quest Diagnostics (DGX) Expected to Beat Earnings Estimates: Should You Buy?

Quest Diagnostics (DGX) second-quarter results are likely to have reflected the solid base business performance and benefits from acquisitions.

Quest Diagnostics (DGX) to Post Q2 Earnings: What's in Store?

Quest Diagnostics (DGX) collaborates with Envision Sciences to bring a novel prosate cancer biomarker test.

Quest Diagnostics (DGX) Brings New Test for Prostate Cancer

Lab service utilizes Envision Science's proprietary biomarkers and technology with a goal of improving diagnosis and grading of prostate cancer SECAUCUS, N.J. and MELBOURNE, Australia , July 13, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the leading provider of diagnostic information services, today announced the launch of a novel prostate cancer biomarker test through its subspecialty pathology business, AmeriPath, in collaboration with  Envision Sciences.

Quest Diagnostics Launches Novel Prostate Cancer Test Aimed at Improving Diagnosis and Grading

SECAUCUS, N.J. , July 13, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced it has been named to the 2023  Disability Equality Index®  (DEI) Best Places to Work for Disability Inclusion by Disability: IN and the American Association of People with Disabilities (AAPD).

Quest Diagnostics Named a 'Best Place to Work for Disability Inclusion' for Sixth Consecutive Year

First consumer genetic health test under the Quest brand provides insights based on DNA, with unique features that include next-generation sequencing, robust support services, physician ordering, and access to one-on-one genetic counseling SECAUCUS, N.J. , July 11, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the leader in diagnostic information services, today announced the launch of its first consumer-initiated genetic test, now exclusively available through the company's consumer health business at questhealth.com.

Quest Launches Consumer-Initiated Genetic Test on questhealth.com to Deliver Personalized, Actionable Health Risk Insights

The Proov Confirm home collection kit can be purchased now on Quest Diagnostics' questhealth.com for $29.

Quest Diagnostics' (DGX) New Pact to Get Home Fertility Test

First and only FDA-cleared PdG (progesterone metabolite) home test to help confirm successful ovulation SECAUCUS, N.J. , July 6, 2023 /PRNewswire/ -- Women seeking to start or expand a family can now access the Proov Confirm PdG home collection kit for assessing fertility through questhealth.com.

Quest and Proov Collaborate to Bring Novel Home Fertility Test to Women Through questhealth.com

American Eagle Outfitters

City Office REIT

Campbell Soup

Gentex

Lincoln National

NetApp

Sysco

Wabash National

In the fast-paced and unpredictable nature of the stock market, investors are constantly on the lookout for strategies that can secure stable returns in a tumultuous environment.

10 Stocks You Could Capture Dividends From This July

Quest Diagnostics (DGX) is dedicated to create cutting-edge laboratory tests to help assess patient risk for dementia and other degenerative diseases.

Quest Diagnostics (DGX) Presents New Data on Disease Testing

Quest Diagnostics (DGX) will use MRD technology to create new blood-based clinical lab services for solid tumour cancers that will be available starting in 2024.

Quest Diagnostics' (DGX) New Buyout Expands Cancer Portfolio

SECAUCUS, N.J. , June 21, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report second quarter 2023 financial results on Wednesday, July 26, 2023, before the market opens.

Quest Diagnostics to Release Second Quarter 2023 Financial Results on July 26, 2023

SECAUCUS, N.J. , June 21, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the nation's leading provider of diagnostic information services, today announced that it has completed its previously announced acquisition of Haystack Oncology.

News for Quest Diagnostics Stock (DGX)